Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 25, 2026

Essential Utilities Reports Financial Results for Full Year 2025

View original at finance.yahoo.com
Essential Utilities Reports Financial Results for Full Year 2025 Earnings per share increases to $2.20 for Full Year 2025 Record $1.4 billion invested in infrastructure during the year Shareholder approval secured for announced merger with American Water BRYN MAWR, Pa., February 25, 2026--(BUSINESS WIRE)--Essential Uti…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • With shareholder approval of merger with American Water, company is well-positioned to deliver for stakeholders for generations to come

    80% confidence
  • Merger with American Water remains on track for closing in the first quarter of 2027

    80% confidence
  • Team achieved excellence in operations, continuing to execute $450 million PFAS capital plan and exceeding Intelis gas meter installation goal

    80% confidence
  • Pipeline of potential water and wastewater municipal acquisitions represents approximately 400,000 total customers

    80% confidence
  • Anticipated growth in long-term earnings per share at a compounded annual growth rate of 5 to 7% from adjusted 2024 earnings per share of $1.97 for three-year period through 2027

    80% confidence
  • 2025 was truly a banner year for the company

    80% confidence
  • In 2026, regulated infrastructure investments are expected to be $1.7 billion

    80% confidence
  • Company has multiyear plan to ensure that finished water does not exceed federal maximum contaminant level of six EPA-regulated PFAS chemicals

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com